India's No.1 PU & Degree With Integrated IAS & IPS(UPSC/PSC) Training College.
RARE-DISEASE DRUGS AS INDIA’S NEXT PHARMA FRONTIER Syllabus: GS-3: Issues related to development and management of social Sectors- Health GS 3: Research And Development Why in the News? India is exploring how its pharmaceutical manufacturing strength, large patient population, and evolving rare-disease policy can be leveraged to make expensive orphan drugs more accessible while creating …
Read MoreALZHEIMER’S BLOOD TEST AIDS EARLY DETECTION BUT LIMITATIONS Why in the News? A blood test for Alzheimer’s disease biomarkers, already cleared in the U.S. and available in India, can detect biological changes linked to the disease. However, experts caution that it is not a general screening test, particularly for people without symptoms. Science Behind Alzheimer’s …
Read MorePRIP SCHEME: BOOSTING INDIA’S PHARMA AND MEDTECH INNOVATION ECOSYSTEM Why in the News? The Department of Pharmaceuticals has announced the second call for applications under the Promotion of Research and Innovation in Pharma & MedTech (PRIP) Scheme, with a total financial outlay of ₹5,000 crore. The scheme seeks to strengthen India’s domestic R&D, innovation, commercialisation …
Read MoreNovo Nordisk Launches Once-Weekly Insulin ‘Awiqli’ in India Why in the News? Danish pharmaceutical company Novo Nordisk has launched Awiqli, a once-weekly basal insulin, in India, marking a significant milestone in strategic partnerships between Denmark and India in the healthcare sector. Its generic name is insulin icodec. The medicine is designed to reduce the frequency …
Read MoreSCIENTISTS FIND A BLOOD TEST THAT PREDICTS LUNG CANCER YEARS EARLY Why in the News? Major Discovery: Scientists led by the Francis Crick Institute, London identified a 14-protein signature in blood plasma that can predict lung cancer years before diagnosis. Published Study: The findings were published in the journal Cell and were based on data …
Read MoreINDIA NEEDS INNOVATIVE STRATEGIES TO ELIMINATE TB Syllabus: GS 2: Issues related to the Social sector : Health care. Government policies and interventions. Why in the News? India’s fight against Tuberculosis (TB) has gained momentum following encouraging results from the PreVenTB Trial, which demonstrated significant efficacy of indigenous vaccines against extrapulmonary TB. The findings …
Read MoreIndian Antibiotic Innovation Reaches Global Healthcare Stage Syllabus: GS-2: Health, Important International Institutions GS-3:Government Policies & Interventions Why in the News ? The novel antibiotic Zaynich recently received approval from the U.S. Food and Drug Administration (FDA), marking a significant milestone for India’s pharmaceutical innovation ecosystem. The achievement highlights India’s growing capability in drug discovery …
Read MoreINDIA’S FIRST ALZHEIMER’S DISEASE-MODIFYING THERAPY Why in the News? Drug Launch: Eli Lilly launched donanemab in India under the brand name Lormalzi for Alzheimer’s treatment. First Therapy: It is the first Alzheimer’s disease-modifying therapy commercially launched in India for early-stage patients. High Cost: The treatment costs around ₹91,688 per dose and requires monthly infusions for …
Read MoreSEMAGLUTIDE GENERICS EXPAND INDIA’S GLP-1 DRUG MARKET Why in the News? The launch of generic versions of semaglutide has led to a 75% rise in sales of GLP-1 drugs in India within one month. Sales volume of semaglutide increased from 25,000 units in February to 1.7 lakh units in April 2026 after patent expiry of …
Read MoreNovel Method Revives Antibiotic Effectiveness Against Resistant Bacteria Why in the News ? Researchers from IIT Bombay have developed a novel approach to tackle antimicrobial resistance (AMR) by restoring the effectiveness of existing antibiotics. The innovation uses DNA aptamers and liposomes to disable bacterial resistance mechanisms, offering a breakthrough in infection treatment that aligns with …
Read More
